Patients, n

48

Age (years, median/range)

54 (19-77)

Sex (female/male), n (%)

16 (33) / 32 (67)

Histology:  Anaplastic Large-Cell Lymphoma,

                       13 of whom ALK-, 6 ALK+, 2 ALK not tested

                   Peripheral T-Cell Lymphoma (NOS and similar)

                   Angioimmunoblastic T-Cell Lymphoma

                   Enteropathy-Associated T-Cell Lymphoma

                   Other T-cell lymphomas, n (%)  

Stage (Ann Arbor) 1^st-line ASCT: I (enteropathy-associated TL)

                                                       II

                                                       III

                                                       IV

IPI at 1^st-line chemotherapy: low risk

                                               low-intermediate risk

                                               high-intermediate risk

                                               high risk

21 (44)

12 (25)

11 (23)

  2 (4)

  2 (4)

1 (4)

  2 (8)

11 (44)

11 (44)

  7 (28)

11 (44)

 4 (16)

  1 (4)

Prior treatment with anthracyclines (CHOP or CHOEP), n (%)

48 (100)

High-dose therapy: BEAM

                                Mega-CHOEP

                                TBI/Cyclophosphamide

Treatment line: 1^st-line ASCT, n (%)

                          2^nd-line ASCT, n (%)

                          3^rd-line ASCT, n (%)

Time from initial diagnosis to 1^st relapse in 2^nd-line ASCT, median/range (mo)

40 (83)

  6 (13)

  2 (4)

25 (52)

13 (27)

10 (21)

16 (2-123)

Time from initial diagnosis to 1^st relapse in 3^rd-line ASCT, median/range (mo)

Refractory to 2^nd-line chemotherapy, n (%)

Second relapse, n (%)

LDH: elevated at 1^st-line ASCT, n (%),  

          elevated at 2^nd-line ASCT, n (%),  

          elevated at 3^rd-line ASCT, n (%),

          no information at 3^rd-line ASCT                                            

7 (1-44)

10 (21)

0

1 (4)

1 (8)

4 (40)

1 (10)

Remission status: CR/PR/SD/PD at 1st-line ASCT, n

                             CR/PR/SD/PD/ED/NI after 1st-line ASCT, n

                             CR/PR/SD/PD at 2nd-line ASCT, n

                             CR/PR/SD/PD/ED after 2nd-line ASCT, n

                             CR/PR/SD/PD at 3rd-line ASCT, n

                             CR/PR/SD/PD/ED after 3rd-line ASCT, n

4/21/0/0

14/8/0/1/1/1

8/5/0/0

10/1/0/1/1

0/1/5/4

3/1/1/3/2

Radiotherapy after 1^st-line ASCT, n (%)

Radiotherapy after 2^nd-line ASCT, n (%)

Radiotherapy after 3^rd-line ASCT, n (%)

Allogeneic stem cell transplantation after 1^st-line ASCT, n (%) 

3 (12)

2 (15)

2 (20)

4 (16)